Explore the words cloud of the NextGen IO project. It provides you a very rough idea of what is the project "NextGen IO" about.
The following table provides information about the project.
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
|Coordinator Country||Spain [ES]|
|Total cost||1˙993˙575 €|
|EC max contribution||1˙993˙575 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2019-02-01 to 2024-01-31|
Take a look of project's partnership.
|1||ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS||ES (DERIO VIZCAYA)||coordinator||1˙993˙575.00|
NextGen_IO has a core focus on immuno-oncology, specifically on target discovery and drug development, to exploit several opportunities that the hypoxia pathway in T cells offers for the treatment of cancer. It is well recognised that the clinical response of immunotherapies depends on the ability of T-cells to mount an effective effector response, persist in treated patients and avoid exhaustion and toxicities. Several approaches to immunotherapy have shown promise in clinical trials, especially the use of immune checkpoint inhibitors and, more recently, autologous adoptive T-cell therapies. However, current state-of-the-art immunotherapies are only effective in a small fraction of patients, offering a medical need to be addressed in several cancer types. Importantly, the tumor microenvironment has specific features that impact the immune response, including decreased oxygenation, aberrant vascularization and altered nutrient availability; all these influence the success of immunotherapies. During the last 10 years, my research has been focused on elucidating the role of the oxygen sensing machinery in T cell function, and the link of hypoxia-driven metabolism and epigenetic modifications with T cell differentiation into effector and memory T cells within the context of cancer immunotherapy. The current proposal aims to exploit these previous findings with a multi-disciplinary strategy, to deliver several early-stage drug discovery outputs.
The main objectives are: 1. Development of a novel small molecule inhibitor to modulate the hypoxic response in T cells. 2. Therapeutic target discovery in T cells, focused on hypoxia-driven epigenetic modifications. 3. Development of hypoxia-inducible molecular switches for adoptive T cell therapy.
Successful completion of the project will allow me to further innovate and consolidate my position as a leader in this field, harness this pathway for therapeutic potential and explore potential combinatorial approaches.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEXTGEN IO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEXTGEN IO" are provided by the European Opendata Portal: CORDIS opendata.
Discovery and Characterization of Hydrogen-Based High-Temperature SuperconductorsRead More
Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin DomainsRead More
The Enemy of the Good: Towards a Theory of Moral ProgressRead More